CAP TODAY Webinars

Webinar presenters David Chi, PhD, Director of Oncology Product Management, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix, Inc., and Bence Sipos, MD, Molecular Pathology, Baden-Württemberg, Stuttgart, Germany, discusses the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients.

Webinar presenter Karen Raraigh, MGC, CGCD, Assistant Professor of Genetic Medicine at Johns Hopkins University, discusses how expanded genetic testing is playing an increasingly vital role in the management of Cystic Fibrosis (CF), helping to elevate the standard of care.

Webinar presenter Raza Hoda, MD, Staff Pathologist, Cleveland Clinic, Assistant Professor of Pathology, Cleveland Clinic Lerner College of Medicine, discusses the importance of advancements in HER2 testing, including HER2 Ultra Low.

Webinar presenter John Farrell, MD, Director, Microbiology & Serology Labs, Chair & Medical Director, Infection Control & Prevention; OSF St. Francis Medical Center discusses the advantages of implementing metagenomic sequencing in your laboratory.

>
Webinar presenters John Fox, MD, MHA, Brian D. Piening, PhD, and Pierre Del Moral, PhD, MBA discuss how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes.

Webinar presenters Melanie Pollan, PhD, Alan H. B. Wu, PhD, and Christopher DeFilippi, MD, discuss how the Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use.

Webinar presenters Gwen Clarke, MD, FRCPC, Hematopathology and Transfusion Medicine, Island Health, Victoria British Columbia Canada, and Clinical Professor, Department of Laboratory Medicine Pathology, University of Alberta, and Nancy Robitaille, MD, FRCPC, Vice-President, Transfusion Medicine, Héma-Québec, Montreal Canada Hematology-Oncology, CHU Sainte-Justine, Montreal, Canada and Clinical Professor, Department of Pediatrics, Université de Montréal discuss how advancements in non-invasive prenatal testing (NIPT) for fetal RHD are transforming targeted antenatal prophylaxis with RhIG.